Income Statement
BIOCRYST PHARMACEUTICALS INC
BCRX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | - | - | - | 25.19 | 26.35 | 48.26 | 13.61 | 17.33 | 26.29 | 19.64 |
|
Cost of Revenue
|
19.08 | 12.27 | 4.48 | 6.41 | 7.23 | 1.55 | 3.73 | 0.00 | - | - | - | - | - | - | - |
|
Gross Profit
|
-19.08 | -12.27 | -4.48 | -6.41 | -7.23 | -1.55 | -3.73 | - | 25.19 | 26.35 | 48.26 | 13.61 | 17.33 | 26.29 | 19.64 |
|
Operating Expenses
|
514.77 | 440.77 | 430.46 | 412.67 | 327.63 | 190.89 | 144.19 | 114.46 | 80.90 | 72.26 | 85.81 | 59.26 | 47.95 | 58.29 | 69.23 |
|
Research & Development
|
166.13 | 174.64 | 216.57 | 253.30 | 208.81 | 122.96 | 107.07 | 84.95 | 66.96 | 61.01 | 72.76 | 51.80 | 42.73 | 51.46 | 56.90 |
|
Selling, General & Administrative
|
348.65 | 266.13 | 213.89 | 159.37 | 118.82 | 67.93 | 37.12 | 29.51 | 13.93 | 11.25 | 13.05 | 7.46 | 5.22 | 6.83 | 12.33 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-533.85 | -453.04 | -434.94 | -419.08 | -334.86 | -192.44 | -147.92 | -114.46 | -55.71 | -45.91 | -37.55 | -45.65 | -30.62 | -32.00 | -49.59 |
|
Non-Operating Income
|
-73.60 | -84.41 | -208.71 | -174.69 | -153.05 | - | - | - | - | - | - | - | - | - | - |
|
Interest Income
|
10.67 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Interest Expense
|
23.27 | 39.87 | 108.24 | 99.09 | 59.29 | 14.50 | 11.89 | 9.18 | 8.57 | 6.49 | 5.20 | 5.00 | 4.78 | 4.67 | 3.77 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Income Before Tax
|
267.39 | -86.95 | -226.23 | -244.38 | -181.81 | -182.81 | - | - | - | - | - | - | - | - | - |
|
Income Tax Expense
|
3.53 | 1.93 | 0.31 | 2.73 | 2.25 | - | - | - | - | - | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
263.86 | -88.88 | -226.54 | -247.12 | -184.06 | -182.81 | 108.90 | -101.25 | -65.78 | -55.14 | -43.02 | -45.19 | -30.11 | -39.08 | -56.95 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-532.46 | -451.79 | -433.29 | -417.64 | -334.08 | -191.70 | -147.19 | -113.69 | -55.01 | -45.43 | -37.37 | -45.47 | -30.32 | -31.37 | -49.59 |
|
Earnings Per Share (Basic)
|
1.26 | -0.43 | -1.18 | -1.33 | - | - | - | - | - | - | - | - | - | - | - |
|
Diluted EPS
|
1.21 | -0.43 | -1.18 | -1.33 | - | - | - | - | - | - | - | - | - | - | - |
|
Weighted Average Shares
|
209.89 | 206.70 | 192.20 | 185.91 | - | - | - | - | - | - | - | - | - | - | - |
|
Diluted Weighted Avg Shares
|
218.58 | 206.70 | 192.20 | 185.91 | 179.12 | 167.27 | 115.60 | 103.19 | 84.45 | 73.70 | 72.90 | - | - | - | - |
|
Comprehensive Income
|
262.98 | -89.30 | -225.23 | -247.27 | -183.89 | -182.85 | -108.56 | -101.31 | -66.01 | -54.95 | -43.10 | -45.32 | -30.13 | -39.09 | -57.01 |